Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.
CTA (Cancer/Testis Antigens)
Cancer Biomarker(s)
Cancer Therapeutics
Glioblastoma
HLA (Human Leukocytes Antigen)
Immunoaffinity
Immunology
Immunotherapy
MHC (Major Histocompatibility Complex)
Peptidomics
Plasma or Serum Analysis
Journal
Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
25
04
2019
entrez:
3
6
2019
pubmed:
4
6
2019
medline:
22
1
2020
Statut:
ppublish
Résumé
Glioblastoma multiforme (GBM) is the most aggressive brain tumor with poor prognosis to most patients. Immunotherapy of GBM is a potentially beneficial treatment option, whose optimal implementation may depend on familiarity with tumor specific antigens, presented as HLA peptides by the GBM cells. Further, early detection of GBM, such as by a routine blood test, may improve survival, even with the current treatment modalities. This study includes large-scale analyses of the HLA peptidome (immunopeptidome) of the plasma-soluble HLA molecules (sHLA) of 142 plasma samples, and the membranal HLA of GBM tumors of 10 of these patients' tumor samples. Tumor samples were fresh-frozen immediately after surgery and the plasma samples were collected before, and at multiple visits after surgery. In total, this HLA peptidome analysis involved 52 different HLA allotypes and resulted in the identification of more than 35,000 different HLA peptides. Strong correlations were observed in the signal intensities and in the repertoires of identified peptides between the tumors and plasma-soluble HLA peptidomes of the individual patients, whereas low correlations were observed between these HLA peptidomes and the tumors' proteomes. HLA peptides derived from Cancer/Testis Antigens (CTAs) were selected based on their presence among the HLA peptidomes of the patients and absence of expression of their source genes from any healthy and essential human tissues, except from immune-privileged sites. Additionally, peptides were selected as potential biomarkers if their levels in the plasma-sHLA peptidome were significantly reduced after the removal of tumor mass. The CTAs identified among the analyzed HLA peptidomes provide new opportunities for personalized immunotherapy and for early diagnosis of GBM.
Identifiants
pubmed: 31154438
pii: S1535-9476(20)31824-7
doi: 10.1074/mcp.RA119.001524
pmc: PMC6553928
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Histocompatibility Antigens Class I
0
Peptides
0
Proteome
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1255-1268Commentaires et corrections
Type : RetractedandRepublishedFrom
Informations de copyright
© 2019 Shraibman et al.
Références
J Clin Invest. 2016 Dec 1;126(12):4690-4701
pubmed: 27841757
Curr Neurol Neurosci Rep. 2015 Jan;15(1):508
pubmed: 25431096
Cancer Treat Rev. 2017 Feb;53:79-97
pubmed: 28088073
Genome Biol. 2009;10(11):R130
pubmed: 19919682
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
pubmed: 9050879
Tissue Antigens. 2008 Oct;72(4):321-34
pubmed: 18700879
Expert Opin Biol Ther. 2016 Oct;16(10):1245-64
pubmed: 27411023
Nature. 1970 Apr 25;226(5243):366-7
pubmed: 5309633
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Proteomics. 2011 Jun;11(11):2336-40
pubmed: 21598389
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Mol Cell Proteomics. 2017 Apr;16(4):642-662
pubmed: 28188227
J Clin Oncol. 2011 Jan 20;29(3):337-44
pubmed: 21149665
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
Proteomics. 2011 Jun;11(12):2528-41
pubmed: 21595034
Ann Transl Med. 2016 Jul;4(14):273
pubmed: 27563660
Annu Rev Pharmacol Toxicol. 2014;54:251-72
pubmed: 24160706
Ther Adv Vaccines. 2014 May;2(3):77-89
pubmed: 24790732
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18769-76
pubmed: 20974924
Proteomics. 2017 Jan;17(1-2):
pubmed: 27928884
J Clin Invest. 2002 Dec;110(12):1813-22
pubmed: 12488431
EMBO J. 2013 Jan 23;32(2):194-203
pubmed: 23258224
Int J Cancer. 1999 Jan 18;80(2):219-30
pubmed: 9935203
Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1591-9
pubmed: 24715725
Brain. 2012 Apr;135(Pt 4):1042-54
pubmed: 22418738
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
Expert Rev Vaccines. 2013 Oct;12(10):1211-7
pubmed: 24090147
J Immunol. 2013 Dec 15;191(12):5831-9
pubmed: 24190657
J Proteome Res. 2006 Apr;5(4):988-94
pubmed: 16602707
Curr Opin Immunol. 2016 Aug;41:9-17
pubmed: 27155075
Neurosurg Rev. 1994;17(3):211-5
pubmed: 7838400
Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9942-E9951
pubmed: 29093164
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
J Neurooncol. 2015 Jul;123(3):433-40
pubmed: 25491947
Elife. 2015 Jul 08;4:
pubmed: 26154972
Science. 1992 Mar 6;255(5049):1261-3
pubmed: 1546328
J Neurooncol. 2015 Jul;123(3):323-30
pubmed: 26070552
Nucleic Acids Res. 2016 Jan 4;44(D1):D313-6
pubmed: 26578587
Oncoimmunology. 2016 Jun 30;5(8):e1204504
pubmed: 27622074
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
J Chromatogr A. 2002 Dec 6;979(1-2):233-9
pubmed: 12498253
Neurotherapeutics. 2017 Apr;14(2):345-357
pubmed: 28389997
Mol Cell Proteomics. 2011 Oct;10(10):O111.011833
pubmed: 21813418
Mol Cell Proteomics. 2015 Dec;14(12):3105-17
pubmed: 26628741
Science. 1970 Nov 6;170(3958):636-7
pubmed: 5470720
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
Nature. 2017 Mar 30;543(7647):723-727
pubmed: 28329770
Anticancer Res. 2017 Jan;37(1):21-33
pubmed: 28011470
BMC Genomics. 2014 Jan 24;15:63
pubmed: 24460756
Mol Cell Proteomics. 2015 Mar;14(3):658-73
pubmed: 25576301
Leuk Res. 2007 Feb;31(2):121-5
pubmed: 16860865
Expert Rev Mol Med. 2011 May 13;13:e17
pubmed: 21676290
Proteomics. 2018 Jun;18(12):e1700284
pubmed: 29505699
Oncotarget. 2016 Feb 2;7(5):5110-7
pubmed: 26819371
Pharmacol Ther. 2015 Aug;152:63-82
pubmed: 25944528
Nucleic Acids Res. 2009 Jan;37(Database issue):D816-9
pubmed: 18838390
Blood. 2015 Sep 3;126(10):1203-13
pubmed: 26138685
Cancer Res. 2002 Oct 15;62(20):5818-27
pubmed: 12384544
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Proteomics. 2017 Oct;17(19):
pubmed: 28834231
Nature. 2008 Apr 3;452(7187):548-52
pubmed: 18385728
Transplantation. 1996 Mar 27;61(6):984-7
pubmed: 8623175
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
Mol Immunol. 2015 Dec;68(2 Pt A):77-80
pubmed: 26118903
Front Oncol. 2015 Jan 29;5:12
pubmed: 25688335
Mol Cell Proteomics. 2016 Jun;15(6):1867-76
pubmed: 26929215
Mol Cell Proteomics. 2015 May;14(5):1361-72
pubmed: 25755296
Can J Neurol Sci. 2016 Jul;43(4):494-502
pubmed: 27324313
Biomed Res Int. 2014;2014:437987
pubmed: 25045677
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Immunol Today. 1995 Mar;16(3):124-7
pubmed: 7718084
Int J Cancer. 2001 Oct 15;94(2):243-51
pubmed: 11668505
BMC Immunol. 2008 Jan 22;9:1
pubmed: 18211710
J Neurooncol. 2013 Feb;111(3):285-94
pubmed: 23263746
Curr Opin Immunol. 2015 Jun;34:1-8
pubmed: 25466393
Mol Cell Proteomics. 2013 Jul;12(7):1853-64
pubmed: 23538226
Mol Cell Proteomics. 2016 Sep;15(9):3058-70
pubmed: 27412690
Proteomics. 2016 May;16(10):1570-80
pubmed: 26992070
Nat Med. 1998 Mar;4(3):321-7
pubmed: 9500606
Proteomics. 2017 Jan;17(1-2):
pubmed: 27862975
Oncoimmunology. 2015 Jan 9;4(4):e974411
pubmed: 26137405
Autoimmun Rev. 2012 Jul;11(9):627-35
pubmed: 22100331